Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
'This acquisition aligns perfectly with Hospira's strategy to improve our margins and cash flow'; Hospira acquires a proven-quality, cost-competitive generic…
FierceBiotech framed the close as Hospira reinforcing its leadership position in generic injectables and lowering its cost position in beta-lactam antibiotics…
Hospira COO Terry Kearney: 'We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Hospira acquired Orchid's generic injectables business in India for ~$400M, including manufacturing and pipeline.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) (this deal) | 2010 | $400M | 23 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
| Hospira Inc. / Javelin Pharmaceuticals, Inc. | 2010 | $145M | 25 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) | 2012 | $200M | 22 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) | 2009 | $400M | 22 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
← Browse all deals · How we score deals
More: 2010 deals · Hospira Inc. deals · Infectious Disease deals